APVO:NSD-Aptevo Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 16.75

Change

-0.15 (-0.89)%

Market Cap

USD 0.08B

Volume

0.05M

Avg Analyst Target

USD 50.00 (+198.51%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-24.46 (-5.38%)

USD183.50B 53.71 41.56
BNTX BioNTech SE

-19.51 (-5.53%)

USD82.28B 18.73 15.10
REGN Regeneron Pharmaceuticals Inc

-7.61 (-1.18%)

USD69.15B 11.67 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.48 (-0.80%)

USD48.02B 24.40 16.63
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-5.90 (-1.53%)

USD37.14B N/A N/A
SGEN Seagen Inc

-4.88 (-2.94%)

USD30.24B 51.86 39.11
GMAB Genmab A/S

-1.45 (-3.23%)

USD28.89B 73.39 8.17
RPRX Royalty Pharma plc

-0.03 (-0.08%)

USD22.54B 30.06 12.50
ALNY Alnylam Pharmaceuticals Inc

+0.45 (+0.24%)

USD22.22B N/A N/A

ETFs Containing APVO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -54.30% 10% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.30% 10% F 6% F
Trailing 12 Months  
Capital Gain 129.77% 88% B+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 129.77% 88% B+ 87% B+
Trailing 5 Years  
Capital Gain 500.36% 90% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 500.36% 90% A- 93% A
Average Annual (5 Year Horizon)  
Capital Gain 857.09% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 857.09% 99% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 2,206.12% 1% F 1% F
Risk Adjusted Return 38.85% 65% D 55% F
Market Capitalization 0.08B 15% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 40.80 22% F 25% F
Price/Book Ratio 6.09 30% F 24% F
Price / Cash Flow Ratio -2.82 23% F 59% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -265.00% 8% F 12% F
Return on Invested Capital -74.96% 29% F 11% F
Return on Assets -35.67% 26% F 8% F
Debt to Equity Ratio 120.85% 10% F 17% F
Technical Ratios  
Short Ratio 1.53 78% C+ 70% C-
Short Percent 2.85% 72% C- 51% F
Beta 7.06 0% N/A 0% N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector